A constitutively active Lck kinase promotes cell proliferation and resistance to apoptosis through signal transducer and activator of transcription 5b activation

Molecular Cancer Research

Volumn 4, Issue 1, 2006, Pages 39-45

  Shi, Mingjian ^a   Cooper, John C ^a   Yu, Chao Lan ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 3; PROTEIN KINASE LCK; STAT PROTEIN; STAT5B PROTEIN; TETRACYCLINE;

APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DNA-BINDING PROTEINS; ENZYME ACTIVATION; HUMANS; INTERLEUKIN-3; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MICE; PHOSPHORYLATION; POINT MUTATION; PROTEIN BINDING; STAT5 TRANSCRIPTION FACTOR; TETRACYCLINE; TRANS-ACTIVATION (GENETICS);

EID: 32944462153     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-05-0202     Document Type: Article

References (41)

1. Sefton BM. The lck tyrosine protein kinase. Oncogene 1991;6:683-6.
2. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004;23:7990-8000.
3. Abraham KM, Levin SD, Marth JD, Forbush KA, Perlmutter RM. Thymic tumorigenesis induced by overexpression of p56lck. Proc Natl Acad Sci U S A 1991;88:3977-81.
4. Marth JD, Disteche C, Pravtcheva D, et al. Localization of a lymphocyte-specific protein tyrosine kinase gene (lck) at a site of frequent chromosomal abnormalities in human lymphomas. Proc Natl Acad Sci U S A 1986;83:7400-4.
5. Wright DD, Sefton BM, Kamps MP. Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia. Mol Cell Biol 1994;14:2429-37.
6. Majolini MB, Boncristiano M, Baldari CT. Dysregulation of the protein tyrosine kinase Lck in lymphoproliferative disorders and in other neoplasias. Leuk Lymphoma 1999;35:245-54.
7. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001;2:467-75.
8. Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene 2004;23:7918-27.
9. Marth JD, Cooper JA, King CS, et al. Neoplastic transformation induced by an activated lymphocyte-specific protein tyrosine kinase (pp56lck). Mol Cell Biol 1988;8:540-50.
10. lck, reveals its oncogenic potential in fibroblasts. Proc Natl Acad Sci U S A 1988;85:4247-51.
11. Yu H, Jove R. The STATs of cancer-new molecular target come of age. Nat Rev Cancer 2004;4:97-105.
12. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002;109:1139-42.
13. Levy DE, Darnell JE. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651-62.
14. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002;109:8121-31.
15. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001;13:211-7.
16. Sonoyama J, Matsumura I, Ezoe S, et al. Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem 2002;277:8076-82.
17. Matsumura I, Nakajima K, Wakao H, et al. Involvement of prolonged Ras activation in thrombopoietin-induced megakaryocytic differentiation of a human factor-dependent hematopoietic cell line. Mol Cell Biol 1998;18:4282-90.
18. Kofoed EM, Hwa V, Little B, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 2003;349:1139-47.
19. Paukku K, Silvennoinen O. STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5. Cytokine Growth Factor Rev 2004;15:435-55.
20. Grimley PM, Dong F, Rui H. Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev 1999;10:131-57.
21. Herrington J, Smit LS, Schwartz J, Carter-Su C. The role of STAT proteins in growth hormone signaling. Oncogene 2000;19:2585-97.
22. Kazansky AV, Kabotyanski EB, Wyszomierski SL, Mancini MA, Rosen JM. Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A. J Biol Chem 1999;274:22484-92.
23. Kazansky AV, Rosen JM. Signal transducers and activators of transcription 5B potentiates v-Src-mediated transformation of NIH-3T3 cells. Cell Growth Differ 2001;12:1-7.
24. Nieborowska-Skorska M, Slupianek A, Xue L, et al. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res 2001;61:6517-23.
25. Xi S, Zhang Q, Gooding WE, Smithgall TE, Grandis JR. Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res 2003;63:6763-71.
26. Leong PL, Xi S, Drenning SD, et al. Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene 2002;21:2846-53.
27. Welte T, Leitenberg D, Dittel BN, et al. STAT5 interaction with the T cell receptor complex and stimulation of T cell proliferation. Science 1999;283:222-5.
28. Yu C-L, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995;269:81-3.
29. Cooper JC, Boustead JN, Yu C-L. Characterization of STAT5B phosphorylation correlating with expression of cytokine-inducible SH2-containing protein (CIS). Cell Signal. In press 2006.
30. Lacronique V, Boureux A, Monni R, et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 2000;95:2076-83.
31. Liu RY, Fan C, Garcia R, Jove R, Zuckerman KS. Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Blood 1999;93:2369-79.
32. Beisenherz-Huss C, Mundt M, Herrala A, et al. Specific DNA binding and transactivation potential of recombinant, purified Stat5. Mol Cell Endocrinol 2001;183:101-12.
33. Lund TC, Coleman C, Horvath E, et al. The Src-family kinase Lck can induce STAT3 phosphorylation and DNA binding activity. Cell Signal 1999;11:789-96.
34. Skorski T. Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer 2002;2:351-60.
35. van Engeland M, Nieland LJW, Ramaekers FCS, Schutte B, Reutelingsperger CPM. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998;31:1-9.
36. Herrmann M, Lorenz HM, Voll R, et al. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res 1994;22:5506-7.
37. Kieslinger M, Woldman I, Moriggl R, et al. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev 2000;14:232-44.
38. Biola A, Lefebvre P, Perrin-Wolff M, et al. Interleukin-2 inhibits glucocorticoid receptor transcriptional activity through a mechanism involving STAT5 (signal transducer and activator of transcription 5) but not AP-1. Mol Endocrinol 2001;15:1062-76.
39. Yu C-L, Jove R, Burakoff SJ. Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase. J Immunol 1997;159:5206-10.
40. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 2004;23:7957-68.
41. Yu C-L, Jin YJ, Burakoff SJ. Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation. J Biol Chem 2000;275:599-604.